Document:

<Page>

                                                                   Exhibit 10.14

                            INDEMNIFICATION AGREEMENT

     This Agreement made and entered into this ____ day of ______, 2006 (the
"AGREEMENT"), by and between Metabolix, Inc., a Delaware corporation (the
"COMPANY," which term shall include, where appropriate, any Entity (as
hereinafter defined) controlled, directly or indirectly, by the Company) and
____________ (the "INDEMNITEE"):

     WHEREAS, it is essential to the Company that it be able to retain and
attract as directors and officers the most capable persons available;

     WHEREAS, increased corporate litigation has subjected directors and
officers to litigation risks and expenses, and the limitations on the
availability of directors and officers liability insurance have made it
increasingly difficult for the Company to attract and retain such persons;

     WHEREAS, the Company's Amended and Restated By-laws (the "BY-LAWS") require
it to indemnify its directors and officers to the fullest extent permitted by
law and permit it to make other indemnification arrangements and agreements;

     WHEREAS, the Company desires to provide Indemnitee with specific
contractual assurance of Indemnitee's rights to full indemnification against
litigation risks and expenses (regardless, among other things, of any amendment
to or revocation of the Company's Second Amended and Restated Certificate of
Incorporation (the "CERTIFICATE OF INCORPORATION") or By-laws or any change in
the ownership of the Company or the composition of its Board of Directors);

     WHEREAS, the Company intends that this Agreement provide Indemnitee with
greater protection than that which is provided by the Company's By-laws; and

     WHEREAS, Indemnitee is relying upon the rights afforded under this
Agreement in becoming or continuing as a director or officer of the Company.

     NOW, THEREFORE, in consideration of the promises and the covenants
contained herein, the Company and Indemnitee do hereby covenant and agree as
follows:

     1.   DEFINITIONS.

          (a)  "CORPORATE STATUS" describes the status of a person who is
               serving or has served (i) as a director of the Company, (ii) as
               an officer of the Company, (iii) in any capacity with respect to
               any employee benefit plan of the Company, or (iv) as a director,
               partner, trustee, officer, employee, or agent of any other Entity
               at the request of the Company. For purposes of subsection (iv) of
               this Section 1(a), if Indemnitee is serving or has served as a
               director, partner, trustee, officer, employee or agent of a
               Subsidiary, Indemnitee shall be deemed to be serving at the
               request of the Company.

<Page>

          (b)  "ENTITY" shall mean any corporation, partnership, limited
               liability company, joint venture, trust, foundation, association,
               organization or other legal entity.

          (c)  "ENTERPRISE" shall mean the Company and any other corporation,
               partnership, joint venture, trust, employee benefit plan or other
               enterprise of which Indemnitee is or was serving at the request
               of the Company as a director, officer, employee, agent or
               fiduciary.

          (d)  "EXPENSES" shall mean all fees, costs and expenses incurred by
               Indemnitee in connection with any Proceeding (as defined below),
               including, without limitation, attorneys' fees, disbursements and
               retainers (including, without limitation, any such fees,
               disbursements and retainers incurred by Indemnitee pursuant to
               Sections 13 and 14(c) of this Agreement), fees and disbursements
               of expert witnesses, private investigators and professional
               advisors (including, without limitation, accountants and
               investment bankers), court costs, transcript costs, fees of
               experts, travel expenses, duplicating, printing and binding
               costs, telephone and fax transmission charges, postage, delivery
               services, secretarial services, and other disbursements and
               expenses.

          (e)  "INDEMNIFIABLE AMOUNTS" shall have the meaning ascribed to that
               term in Section 3 below.

          (f)  "LIABILITIES" shall mean judgments, damages, liabilities, losses,
               penalties, excise taxes, fines and amounts paid in settlement.

          (g)  "PROCEEDING" shall mean any threatened, pending or completed
               claim, action, suit, arbitration, alternate dispute resolution
               process, investigation, administrative hearing, appeal, or any
               other proceeding, whether civil, criminal, administrative,
               arbitrative or investigative, whether formal or informal,
               including a proceeding initiated by Indemnitee pursuant to
               Section 13 of this Agreement to enforce Indemnitee's rights
               hereunder.

          (h)  "SUBSIDIARY" shall mean any corporation, partnership, limited
               liability company, joint venture, trust or other Entity of which
               the Company owns (either directly or through or together with
               another Subsidiary of the Company) either (i) a general partner,
               managing member or other similar interest or (ii) (A) 50% or more
               of the voting power of the voting capital equity interests of
               such corporation, partnership, limited liability company, joint
               venture or other Entity, or (B) 50% or more of the outstanding
               voting capital stock or other voting equity interests of such
               corporation, partnership, limited liability company, joint
               venture or other Entity.

     2.   SERVICES OF INDEMNITEE. In consideration of the Company's covenants
and commitments hereunder, Indemnitee agrees to serve or continue to serve as a
director or officer of the Company. However, this Agreement shall not impose any
obligation on Indemnitee or the

                                        2
<Page>

Company to continue Indemnitee's service to the Company beyond any period
otherwise required by law or by other agreements or commitments of the parties,
if any. Indemnitee may at any time and for any reason resign from such position
(subject to any other contractual obligation or any obligation imposed by
operation of law), upon which event the Company shall have no obligation under
this Agreement to continue Indemnitee in such position. Notwithstanding the
forgoing, this Agreement shall continue in force after Indemnitee has ceased to
serve as a director or officer of the Company.

     3.   INDEMNITY IN THIRD-PARTY PROCEEDINGS. The Company shall indemnify
Indemnitee in accordance with the provisions of this Section 3 if Indemnitee is,
or is threatened to be made, by reason of Indemnitee's Corporate Status, a party
to or a participant in any Proceeding, other than a Proceeding by or in the
right of the Company to procure a judgment in its favor. Pursuant to this
Section 3, Indemnitee shall be indemnified against all Expenses and Liabilities
actually and reasonably incurred by Indemnitee or on his behalf in connection
with such Proceeding or any claim, issue or matter therein (indemnifiable
Expenses and Liabilities collectively referred herein as "INDEMNIFIABLE
AMOUNTS"), if Indemnitee acted in good faith and in a manner he reasonably
believed to be in or not opposed to the best interests of the Company and, in
the case of a criminal Proceeding, had not reasonable cause to believe that his
conduct was unlawful. Indemnitee shall not enter into any settlement in
connection with a Proceeding without the consent of the Company, which shall not
be unreasonably held or delayed.

     4.   INDEMNITY IN PROCEEDINGS BY OR IN THE RIGHT OF THE COMPANY. The
Company shall indemnify Indemnitee in accordance with the provisions of this
Section 4 if Indemnitee is, or is threatened to be made, by reason of
Indemnitee's Corporate Status, a party to or a participant in any Proceeding by
or in the right of the Company to procure a judgment in its favor. Pursuant to
this Section 4, Indemnitee shall be indemnified against all Expenses actually
and reasonably incurred by him or on his behalf in connection with such
Proceeding or any claim, issue or matter therein, if Indemnitee acted in good
faith and in a manner he reasonably believed to be in or not opposed to the best
interests of the Company. No indemnification for Expenses shall be made under
this Section 4 in respect of any claim, issue or matter as to which Indemnitee
shall have been finally adjudged by a court to be liable to the Company, unless
and only to the extent that the Delaware Court of Chancery (the "DELAWARE
CHANCERY COURT") or any court in which the Proceeding was brought shall
determine upon application that, despite the adjudication of liability, but in
view of all the circumstances of the case, Indemnitee is fairly and reasonably
entitled to indemnification for such Expenses as the Delaware Chancery Court or
such other court shall deem proper.

     5.   INDEMNIFICATION FOR EXPENSES OF A PARTY WHO IS WHOLLY OR PARTLY
SUCCESSFUL. If Indemnitee is not wholly successful in such Proceeding but is
successful, on the merits or otherwise, as to one or more but less than all
claims, issues or matters in such Proceeding, the Company shall indemnify
Indemnitee against: (a) all Expenses reasonably incurred by Indemnitee or on
Indemnitee's behalf in connection with each successfully resolved claim, issue
or matter; and (b) any claim, issue or matter related to any such successfully
resolved claim, issue or matter. For purposes of this Agreement, the termination
of any claim, issue or matter in such a Proceeding by dismissal, with or without
prejudice, by reason of settlement, judgment, order or otherwise, shall be
deemed to be a successful result as to such claim, issue or matter.

                                        3
<Page>

     6.   PROCEDURE FOR PAYMENT OF INDEMNIFIABLE AMOUNTS. Indemnitee shall
submit to the Company a written request specifying the Indemnifiable Amounts for
which Indemnitee seeks payment under Sections 3, 4 or 5 of this Agreement and
the basis for the claim. The Company shall pay such Indemnifiable Amounts to
Indemnitee promptly upon receipt of its request. At the request of the Company,
Indemnitee shall furnish such documentation and information as are reasonably
available to Indemnitee and necessary to establish that Indemnitee is entitled
to indemnification hereunder.

     7.   INDEMNIFICATION FOR EXPENSES OF A WITNESS. Notwithstanding any other
provision of this Agreement, to the extent that Indemnitee is, by reason of his
Corporate Status, a witness in any Proceeding to which Indemnitee is not a
party, he shall be indemnified against all Expenses actually and reasonably
incurred by him or on his behalf in connection therewith.

     8.   EFFECT OF CERTAIN RESOLUTIONS. Neither the settlement or termination
of any Proceeding nor the failure of the Company to award indemnification or to
determine that indemnification is payable shall create a presumption that
Indemnitee is not entitled to indemnification hereunder. In addition, the
termination of any proceeding by judgment, order, settlement, conviction, or
upon a plea of NOLO CONTENDERE or its equivalent shall not create a presumption
that Indemnitee did not act in good faith and in a manner which Indemnitee
reasonably believed to be in or not opposed to the best interests of the Company
or, with respect to any criminal Proceeding, had reasonable cause to believe
that Indemnitee's action was unlawful.

     9.   EXCLUSIONS. Notwithstanding any provision in this Agreement to the
contrary, the Company shall not be obligated under this Agreement to make any
indemnity in connection with any claim made against Indemnitee:

          (a)  for which payment has actually been made to or on behalf of
               Indemnitee under any insurance policy or other indemnity
               provision, except with respect to any excess beyond the amount
               paid under any insurance policy or other indemnity provisions;

          (b)  for an accounting of profits made from the purchase and sale (or
               sale and purchase) by Indemnitee of securities of the Company
               within the meaning of Section 16(b) of the Securities Exchange
               Act of 1934, as amended, or similar provisions of state statutory
               law or common law; or

          (c)  for which payment is prohibited by applicable law.

     10.  AGREEMENT TO ADVANCE EXPENSES; UNDERTAKING. The Company shall advance
all Expenses incurred by or on behalf of Indemnitee in connection with any
Proceeding, including a Proceeding by or in the right of the Company, in which
Indemnitee is involved by reason of such Indemnitee's Corporate Status within
ten (10) calendar days after the receipt by the Company of a written statement
from Indemnitee requesting such advance or advances from time to time, whether
prior to or after final disposition of such Proceeding. Advances shall be
unsecured and interest free. Advances shall be made without regard to
Indemnitee's ability to

                                        4
<Page>

repay the expenses and without regard to Indemnitee's ultimate entitlement to
indemnification under the other provisions of this Agreement. To the extent
required by Delaware law, Indemnitee hereby undertakes to repay any and all of
the amount of indemnifiable Expenses paid to Indemnitee if it is finally
determined by a court of competent jurisdiction that Indemnitee is not entitled
under this Agreement to indemnification with respect to such Expenses. This
undertaking is an unlimited general obligation of Indemnitee.

     11.  PROCEDURE FOR ADVANCE PAYMENT OF EXPENSES. Indemnitee shall submit to
the Company a written request specifying the Expenses for which Indemnitee seeks
an advancement under Section 10 of this Agreement, together with documentation
evidencing that Indemnitee has incurred such Expenses (which shall include
invoices received by Indemnitee in connection with such Expenses but, in the
case of invoices in connection with legal services, any reference to legal work
performed or to expenditures made that would cause Indemnitee to waive any
privilege accorded by applicable law shall not be included with the invoice).
Advances under Section 10 shall be made no later than ten (10) calendar days
after the Company's receipt of such request. If a claim for advancement of
Expenses hereunder by Indemnitee is not paid in full by the Company within ten
(10) calendar days after receipt by the Company of documentation of Expenses and
the required undertaking, Indemnitee may at any time thereafter bring suit
against the Company to recover the unpaid amount of the claim and if successful
in whole or in part, Indemnitee shall also be entitled to be paid the expenses
of prosecuting such claim. The burden of proving that Indemnitee is not entitled
to an advancement of expenses shall be on the Company.

     12.  PRESUMPTIONS AND EFFECT OF CERTAIN PROCEEDINGS.

          (a)  In making a determination required to be made under Delaware law
               with respect to entitlement to indemnification hereunder, the
               person, persons or entity making such determination shall presume
               that Indemnitee is entitled to indemnification under this
               Agreement if Indemnitee has submitted a request for
               indemnification in accordance with Section 6 of this Agreement,
               and the Company shall have the burden of proof to overcome that
               presumption in connection with the making of any determination
               contrary to that presumption. Neither the failure of the Company
               or of any person, persons or entity to have made a determination
               prior to the commencement of any action pursuant to this
               Agreement that indemnification is proper in the circumstances
               because Indemnitee has met the applicable standard of conduct,
               nor an actual determination by the Company or by any person,
               persons or entity that Indemnitee has not met such applicable
               standard of conduct, shall be a defense to the action or create a
               presumption that Indemnitee has not met the applicable standard
               of conduct.

          (b)  The termination of any Proceeding or of any claim, issue or
               matter therein, by judgment, order, settlement or conviction, or
               upon a plea of NOLO CONTENDERE or its equivalent, shall not
               (except as otherwise expressly provided in this Agreement) of
               itself adversely affect the right of

                                        5
<Page>

               Indemnitee to indemnification or create a presumption that
               Indemnitee did not act in good faith and in a manner which he
               reasonably believed to be in or not opposed to the best interests
               of the Company or, with respect to any criminal Proceeding, that
               Indemnitee had reasonable cause to believe that his conduct was
               unlawful.

          (c)  For purposes of any determination of good faith, Indemnitee shall
               be deemed to have acted in good faith if Indemnitee's action is
               based on the records or books of account of the Enterprise,
               including financial statements, or on information supplied to
               Indemnitee by the officers of the Enterprise in the course of
               their duties, or on the advice of legal counsel for the
               Enterprise or the Board of Directors or counsel selected by any
               committee of the Board of Directors or on information or records
               given or reports made to the Enterprise by an independent
               certified public accountant or by an appraiser, investment banker
               or other expert selected with reasonable care by the Company or
               the Board of Directors or any committee of the Board of
               Directors. The provisions of this Section 12(c) shall not be
               deemed to be exclusive or to limit in any way the other
               circumstances in which the Indemnitee may be deemed to have met
               the applicable standard of conduct set forth in this Agreement.

          (d)  The knowledge and/or actions, or failure to act, of any director,
               officer, agent or employee of the Enterprise shall not be imputed
               to Indemnitee for purposes of determining the right to
               indemnification under this Agreement.

     13.  REMEDIES OF INDEMNITEE.

          (a)  RIGHT TO PETITION COURT. In the event that Indemnitee makes a
               request for payment of Indemnifiable Amounts under Sections 3, 4
               and 5 above or a request for an advancement of Expenses under
               Sections 10 and 11 above and the Company fails to make such
               payment or advancement in a timely manner pursuant to the terms
               of this Agreement, Indemnitee may petition the Delaware Chancery
               Court to enforce the Company's obligations under this Agreement.

          (b)  BURDEN OF PROOF. In any judicial proceeding brought under Section
               13(a) above, the Company shall have the burden of proving that
               Indemnitee is not entitled to payment of Indemnifiable Amounts
               hereunder.

          (c)  EXPENSES. The Company agrees to reimburse Indemnitee in full for
               any Expenses incurred by Indemnitee in connection with
               investigating, preparing for, litigating, defending or settling
               any action brought by Indemnitee under Section 13(a) above, or in
               connection with any claim or counterclaim brought by the Company
               in connection therewith, if Indemnitee is successful in whole or
               in part in connection with any such action.

                                        6
<Page>

          (d)  FAILURE TO ACT NOT A DEFENSE. The failure of the Company
               (including its Board of Directors or any committee thereof,
               independent legal counsel, or stockholders) to make a
               determination concerning the permissibility of the payment of
               Indemnifiable Amounts or the advancement of indemnifiable
               Expenses under this Agreement shall not be a defense in any
               action brought under Section 13(a) above, and shall not create a
               presumption that such payment or advancement is not permissible.

     14.  DEFENSE OF THE UNDERLYING PROCEEDING.

          (a)  NOTICE BY INDEMNITEE. Indemnitee agrees to notify the Company
               promptly upon being served with any summons, citation, subpoena,
               complaint, indictment, information, or other document relating to
               any Proceeding which may result in the payment of Indemnifiable
               Amounts or the advancement of Expenses hereunder; PROVIDED,
               HOWEVER, that the failure to give any such notice shall not
               disqualify Indemnitee from the right, or otherwise affect in any
               manner any right of Indemnitee, to receive payments of
               Indemnifiable Amounts or advancements of Expenses unless the
               Company's ability to defend in such Proceeding is materially and
               adversely prejudiced thereby.

          (b)  DEFENSE BY COMPANY. Subject to the provisions of the last
               sentence of this Section 14(b) and of Section 14(c) below, the
               Company shall have the right to defend Indemnitee in any
               Proceeding which may give rise to the payment of Indemnifiable
               Amounts hereunder; PROVIDED, HOWEVER, that the Company shall
               notify Indemnitee of any such decision to defend within thirty
               (30) calendar days of receipt of notice of any such Proceeding
               under Section 14(a) above. The Company shall not, without the
               prior written consent of Indemnitee, consent to the entry of any
               judgment against Indemnitee or enter into any settlement or
               compromise which (i) includes an admission of fault of Indemnitee
               or (ii) does not include, as an unconditional term thereof, the
               full release of Indemnitee from all liability in respect of such
               Proceeding, which release shall be in form and substance
               reasonably satisfactory to Indemnitee. This Section 14(b) shall
               not apply to a Proceeding brought by Indemnitee under Section
               13(a) above or pursuant to Section 22 below.

          (c)  INDEMNITEE'S RIGHT TO COUNSEL. Notwithstanding the provisions of
               Section 14(b) above, if in a Proceeding to which Indemnitee is a
               party by reason of Indemnitee's Corporate Status, (i) Indemnitee
               reasonably concludes that he or she may have separate defenses or
               counterclaims to assert with respect to any issue which may not
               be consistent with the position of other defendants in such
               Proceeding, (ii) a conflict of interest or potential conflict of
               interest exists between Indemnitee and the Company, or (iii) if
               the Company fails to assume the defense of such proceeding in a
               timely manner, Indemnitee shall be entitled to be represented by
               a separate legal counsel of Indemnitee's choice at the expense of
               the Company. In

                                        7
<Page>

               addition, if the Company fails to comply with any of its
               obligations under this Agreement or in the event that the Company
               or any other person takes any action to declare this Agreement
               void or unenforceable, or institutes any action, suit or
               proceeding to deny or to recover from Indemnitee the benefits
               intended to be provided to Indemnitee hereunder, Indemnitee shall
               have the right to retain a counsel of Indemnitee's choice, at the
               expense of the Company, to represent Indemnitee in connection
               with any such matter.

     15.  REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company hereby
represents and warrants to Indemnitee as follows:

          (a)  AUTHORITY. The Company has all necessary power and authority to
               enter into, and be bound by the terms of, this Agreement, and the
               execution, delivery and performance of the undertakings
               contemplated by this Agreement have been duly authorized by the
               Company.

          (b)  ENFORCEABILITY. This Agreement, when executed and delivered by
               the Company in accordance with the provisions hereof, shall be a
               legal, valid and binding obligation of the Company, enforceable
               against the Company in accordance with its terms, except as such
               enforceability may be limited by applicable bankruptcy,
               insolvency, moratorium, reorganization or similar laws affecting
               the enforcement of creditors' rights generally.

     16.  INSURANCE. The Company shall, from time to time, make the good faith
determination whether or not it is practicable for the Company to obtain and
maintain a policy or policies of insurance with a reputable insurance company
providing the Indemnitee with coverage for losses from wrongful acts. For so
long as Indemnitee shall remain a director or officer of the Company and with
respect to any such prior service, in all policies of director and officer
liability insurance, Indemnitee shall be named as an insured in such a manner as
to provide Indemnitee the same rights and benefits as are accorded to the most
favorably insured of the Company's officers and directors. Notwithstanding the
foregoing, the Company shall have no obligation to obtain or maintain such
insurance. The Company shall promptly notify Indemnitee of any good faith
determination not to provide such coverage.

     17.  CONTRACT RIGHTS NOT EXCLUSIVE. The rights to payment of Indemnifiable
Amounts and advancement of indemnifiable Expenses provided by this Agreement
shall be in addition to, but not exclusive of, any other rights which Indemnitee
may have at any time under applicable law, the Company's Certificate of
Incorporation or By-laws, or any other agreement, vote of stockholders or
directors (or a committee of directors), or otherwise, both as to action in
Indemnitee's official capacity and as to action in any other capacity as a
result of Indemnitee's serving as a director or officer of the Company.

     18.  SUCCESSORS. This Agreement shall be (a) binding upon all successors
and assigns of the Company (including any transferee of all or a substantial
portion of the business, stock and/or assets of the Company and any direct or
indirect successor by merger or consolidation

                                        8
<Page>

or otherwise by operation of law) and (b) binding on and shall inure to the
benefit of the heirs, personal representatives, executors and administrators of
Indemnitee. This Agreement shall continue for the benefit of Indemnitee and such
heirs, personal representatives, executors and administrators after Indemnitee
has ceased to have Corporate Status.

     19.  SUBROGATION. In the event of any payment of Indemnifiable Amounts
under this Agreement, the Company shall be subrogated to the extent of such
payment to all of the rights of contribution or recovery of Indemnitee against
other persons, and Indemnitee shall take, at the request of the Company, all
reasonable action necessary to secure such rights, including the execution of
such documents as are necessary to enable the Company to bring suit to enforce
such rights.

     20.  CHANGE IN LAW. To the extent that a change in Delaware law (whether by
statute or judicial decision) shall permit broader indemnification or
advancement of expenses than is provided under the terms of the By-laws and this
Agreement, Indemnitee shall be entitled to such broader indemnification and
advancements, and this Agreement shall be deemed to be amended to such extent.

     21.  SEVERABILITY. Whenever possible, each provision of this Agreement
shall be interpreted in such a manner as to be effective and valid under
applicable law, but if any provision of this Agreement, or any clause thereof,
shall be determined by a court of competent jurisdiction to be illegal, invalid
or unenforceable, in whole or in part, such provision or clause shall be limited
or modified in its application to the minimum extent necessary to make such
provision or clause valid, legal and enforceable, and the remaining provisions
and clauses of this Agreement shall remain fully enforceable and binding on the
parties.

     22.  INDEMNITEE AS PLAINTIFF. Except as provided in Section 13(c) of this
Agreement and in the next sentence, Indemnitee shall not be entitled to payment
of Indemnifiable Amounts or advancement of indemnifiable Expenses with respect
to any Proceeding brought by Indemnitee against the Company, any Entity which it
controls, any director or officer thereof, or any third party, unless the Board
of Directors of the Company has consented to the initiation of such Proceeding.
This Section 22 shall not apply to counterclaims or affirmative defenses
asserted by Indemnitee in an action brought against Indemnitee.

     23.  MODIFICATIONS AND WAIVER. Except as provided in Section 20 above with
respect to changes in Delaware law which broaden the right of Indemnitee to be
indemnified by the Company, no supplement, modification or amendment of this
Agreement shall be binding unless executed in writing by each of the parties
hereto. No waiver of any of the provisions of this Agreement shall be deemed or
shall constitute a waiver of any other provisions of this Agreement (whether or
not similar), nor shall such waiver constitute a continuing waiver.

     24.  GENERAL NOTICES. All notices, requests, demands and other
communications hereunder shall be in writing and shall be deemed to have been
duly given (a) when delivered by hand, (b) when transmitted by facsimile and
receipt is acknowledged, or (c) if mailed by certified

                                        9
<Page>

or registered mail with postage prepaid, on the third business day after the
date on which it is so mailed:

          (i)   If to Indemnitee, to:
               ___________________________
               ___________________________
               ___________________________
               ___________________________

          (ii)  If to the Company, to:

               Metabolix, Inc.
               21 Erie Street
               Cambridge, Massachusetts 02139
               Attention:  General Counsel

or to such other address as may have been furnished in the same manner by any
party to the others.

          25.  GOVERNING LAW; CONSENT TO JURISDICTION; SERVICE OF PROCESS. This
Agreement shall be governed by and construed in accordance with the laws of the
State of Delaware without regard to its rules of conflict of laws. Each of the
Company and the Indemnitee hereby irrevocably and unconditionally consents to
submit to the exclusive jurisdiction of the Delaware Chancery Court and the
courts of the United States of America located in the State of Delaware (the
"DELAWARE COURTS") for any litigation arising out of or relating to this
Agreement and the transactions contemplated hereby (and agrees not to commence
any litigation relating thereto except in such courts), waives any objection to
the laying of venue of any such litigation in the Delaware Courts and agrees not
to plead or claim in any Delaware Court that such litigation brought therein has
been brought in an inconvenient forum. Each of the parties hereto agrees, (a) to
the extent such party is not otherwise subject to service of process in the
State of Delaware, to appoint and maintain an agent in the State of Delaware as
such party's agent for acceptance of legal process, and (b) that service of
process may also be made on such party by prepaid certified mail with a proof of
mailing receipt validated by the United States Postal Service constituting
evidence of valid service. Service made pursuant to (a) or (b) above shall have
the same legal force and effect as if served upon such party personally within
the State of Delaware. For purposes of implementing the parties' agreement to
appoint and maintain an agent for service of process in the State of Delaware,
each such party does hereby appoint The Corporation Trust Company, 1209 Orange
Street, Wilmington, New Castle County, Delaware 19801, as such agent and each
such party hereby agrees to complete all actions necessary for such appointment.

                            [signature page follows]

                                       10
<Page>

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of
the day and year first above written.

                                         METABOLIX, INC.

                                         By:
                                            ------------------------------------
                                            Name:
                                            Title:

                                         INDEMNITEE

                                         ---------------------------------------
                                            [Name]<Page>

WHENEVER CONFIDENTIAL INFORMATION IS OMITTED HEREIN (SUCH OMISSIONS ARE DENOTED
BY AN ASTERISK*), SUCH CONFIDENTIAL INFORMATION HAS BEEN SUBMITTED SEPARATELY TO
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT

                                LICENSE AGREEMENT

     This Agreement is made and entered into this 1st day of October, 1999, (the
"Effective Date") by and between METABOLIX, Inc. a corporation duly organized
and existing under the laws of the State of Delaware and having its principal
office at 303 Third Street, Cambridge, Massachusetts 02142 (hereinafter referred
to as "METABOLIX"), and TEPHA, Inc., a corporation duly organized under the laws
of the State of Delaware and having its principal office at 303 Third Street,
Cambridge, Massachusetts 02142 (hereinafter referred to as "TEPHA").

                                   WITNESSETH

     WHEREAS, METABOLIX, is the owner of the METABOLIX PATENT RIGHTS (as later
defined herein), and related technology, and has the right to grant licenses
under said METABOLIX PATENT RIGHTS;

     WHEREAS, METABOLIX is the licensee from the Massachusetts Institute of
Technology (hereinafter referred to as "MIT") of the MIT PATENT RIGHTS (as later
defined herein), and has the right to grant sublicenses under said MIT PATENT
RIGHTS;

     WHEREAS, METABOLIX desires to have the PATENT RIGHTS commercialized in the
FIELD OF USE, and is willing to grant a license thereunder; and

     WHEREAS, LICENSEE desires to obtain a license under the PATENT RIGHTS upon
the terms and conditions hereinafter set forth.

     NOW THEREFORE, in consideration of the premises and the mutual covenants
contained herein, the parties hereto agree as follows:

*    CONFIDENTIAL TREATMENT REQUESTED

<Page>

1.   DEFINITIONS

     For the purposes of this Agreement, the following words and phrases shall
have the following meanings:

     1.1. "TEPHA" and "METABOLIX" shall include "AFFILIATES" defined as a
          related company of TEPHA or METABOLIX, respectively, the voting stock
          of which is directly or indirectly at least fifty percent (50%) owned
          and controlled by TEPHA or METABOLIX, respectively, an organization
          which directly or indirectly controls more than fifty percent (50%) of
          the voting stock of TEPHA or METABOLIX, respectively, and an
          organization the majority ownership of which is directly or indirectly
          common to the ownership of TEPHA or METABOLIX, respectively.

     1.2. "PATENT RIGHTS" shall mean all of the following METABOLIX and MIT
          intellectual property, respectively, the "METABOLIX PATENT RIGHTS" and
          the MIT PATENT RIGHTS":

          1.2.1. the United States patents listed in Appendix A;

          1.2.2. the United States patent applications listed in Appendix A and
                 United States patent applications filed after the EFFECTIVE
                 DATE on IMPROVEMENTS, and divisionals, continuations and claims
                 of continuation-in-part applications which shall be directed to
                 subject matter specifically described in such patent
                 applications, and the resulting patents;

          1.2.3. any patents resulting from reissues or reexaminations of the
                 United States patents described in 1.2.1 and 1.2.2 above;

          1.2.4. the Foreign patents listed in Appendix A;

          1.2.5. the Foreign patent applications listed in Appendix A, and
                 divisionals, continuations and claims of continuation-in-part
                 applications which shall be directed to subject matter
                 specifically described in such Foreign patent applications, and
                 the resulting patents;

*    CONFIDENTIAL TREATMENT REQUESTED

                                       2

<Page>

          1.2.6. Foreign patent applications filed after the EFFECTIVE DATE on
                 any patent application in 1.2.2 and divisionals, continuations
                 and claims of continuation-in-part applications which shall be
                 directed to subject matter specifically described in such
                 patent applications, and the resulting patents; and

          1.2.7. any Foreign patents, resulting from equivalent Foreign
                 procedures to United States reissues and reexaminations, of the
                 Foreign patents described in 1.2.4, 1.2.5 and 1.2.6 above.

     1.3. A "LICENSED PRODUCT" shall mean any product or part thereof which:

          1.3.1. is covered in whole or in part by an issued, unexpired valid
                 claim or a pending claim contained in the PATENT RIGHTS in the
                 country in which any such product or part thereof is made, used
                 or sold; or

          1.3.2. is manufactured by using a process or is employed to practice a
                 process which is covered in whole or in part by an issued,
                 unexpired valid claim or a pending claim contained in the
                 PATENT RIGHTS in the country in which a LICENSED PROCESS is
                 used or in which such product or part thereof is used or sold.

     1.4. A "LICENSED PROCESS" shall mean any process which:

          1.4.1. is covered in whole or in part by an issued, unexpired valid
                 claim or a pending claim contained in the PATENT RIGHTS in the
                 country in which such process is used or in which the LICENSED
                 PRODUCT made thereby is used or sold.

     1.5. "NET SALES" shall mean TEPHA's and its sublicensees' billings for
          LICENSED PRODUCTS and LICENSED PROCESSES produced hereunder less the
          sum of the following:

          1.5.1. discounts allowed in amounts customary in the trade;

          1.5.2. sales, tariff duties and/or use taxes directly imposed and with
                 reference to particular sales;

          1.5.3. outbound transportation prepaid or allowed; and

          1.5.4. amounts allowed or credited on returns.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       3

<Page>

     No deduction shall be made for commissions paid to individuals whether they
     be with independent sales agencies or regularly employed by TEPHA and on
     its payroll, or for cost of collections. LICENSED PRODUCTS shall be
     considered "sold" when invoiced. "NET SALES" shall not include LICENSED
     PRODUCTS sold for clinical testing, research or development purposes. If a
     LICENSED PRODUCT or LICENSED PROCESS shall be distributed or invoiced for a
     discounted price substantially lower than customary in the trade or
     distributed at no cost to AFFILIATES of TEPHA or otherwise, NET SALES shall
     be based on the customary amount billed for such LICENSED PRODUCTS or
     LICENSED PROCESSES.

     Where the LICENSED PRODUCT is a combination product consisting of polymer
     whose composition or manufacture is covered by the PATENT RIGHTS plus other
     materials (such as a growth factor, but not, for example, filler materials)
     that are not covered by the PATENT RIGHTS, then "NET SALES" shall mean the
     NET SALES of the full product multiplied by the fully loaded manufacturing
     cost of the polymer divided by the total fully loaded manufacturing cost of
     the total combination material. When the LICENSED PRODUCT consists of a
     combination product consisting of a component made from the polymer, plus
     other components, then "NET SALES" shall mean NET SALES of the total
     product multiplied by the fully loaded manufacturing cost of the polymer
     component divided by the fully loaded manufacturing cost of the total
     product. By "fully loaded" is meant the cost of goods sold plus overhead
     allocated to production and sale thereof.

     1.6. "FIELD OF USE" shall mean IN VIVO human and veterinary medical use of
          polymers falling within the PATENT RIGHTS, including, without
          limitation, tissue engineering, implantables, medical devices, drug
          delivery and contrast agents, but excluding medical disposables,
          surgical drapes and trays, nutritional and all other diagnostic uses.
          and excluding transgenic plant crop production of polymers.
          "IMPROVEMENT" shall mean an invention conceived and/or reduced to
          practice during the two-year period after the EFFECTIVE DATE and
          dominated by the claims of the PATENT RIGHTS listed on Appendix A and
          owned or CONTROLLED by METABOLIX or TEPHA (excluding any preexisting
          IMPROVEMENT owned or CONTROLLED by any entity as of the

*    CONFIDENTIAL TREATMENT REQUESTED

                                       4

<Page>

          date it becomes a successor or permitted assignee of METABOLIX or
          TEPHA under Article 11).

     1.7. "KNOW-HOW" shall mean technical, manufacturing, regulatory and other
          information, methods, specifications, samples, processes, procedures,
          formulations, test data, protocols, and trade secrets owned or
          CONTROLLED by METABOLIX or TEPHA during the two-year period after the
          EFFECTIVE DATE and relating to the PATENT RIGHTS or to the
          development, manufacture or use of any LICENSED PRODUCTS or LICENSED
          PROCESSES (excluding any preexisting KNOW-HOW owned or CONTROLLED by
          any entity as of the date it becomes a successor or permitted assignee
          of METABOLIX or TEPHA under Article 11).

     1.8. "CONTROL" shall mean with respect to any IMPROVEMENTS or KNOW-HOW, the
          possession of the ability to grant a license or sublicense with
          respect thereto as provided for herein.

     1.9. "FDA" shall mean the United States Food and Drug Administration or any
          successor agency thereof.

2.   GRANT

     2.1. Subject to the terms and conditions of this Agreement, METABOLIX
          hereby grants to TEPHA the worldwide right and license in the FIELD OF
          USE to make, have made, use, lease, sell, offer for sale and import
          the LICENSED PRODUCTS and to practice the LICENSED PROCESSES until the
          expiration of the last to expire of the PATENT RIGHTS, unless this
          Agreement shall be sooner terminated according to the terms hereof.

     2.2  Under the terms of its license with MIT, METABOLIX has agreed that any
          sublicenses granted by it shall provide that the obligations to MIT of
          articles 2, 5, 7, 8, 9, 10, 12, 13 and 15 of its license with MIT
          shall be binding upon the sublicensee as if it were a party to that
          license agreement. METABOLIX further has agreed to attach copies of
          these articles to sublicense agreements, and a copy thereof is
          attached hereto as Appendix C. To the extent of any conflict between

*    CONFIDENTIAL TREATMENT REQUESTED

                                       5

<Page>

          the terms of this Agreement and Appendix C, as to the MIT PATENT
          RIGHTS only, the terms of Appendix C shall prevail.

     2.3  In order to establish a period of exclusivity for TEPHA, METABOLIX
          hereby agrees that it shall not grant any other license to make, have
          made, use, lease, sell, offer for sale or import LICENSED PRODUCTS or
          to utilize LICENSED PROCESSES in the FIELD OF USE and shall not
          practice under the PATENT RIGHTS for its own purposes in the FIELD OF
          USE during the term of this Agreement; provided, however, MIT has
          reserved the right to practice under the MIT PATENT RIGHTS for its own
          noncommercial research purposes.

     2.4  Within six (6) months after the EFFECTIVE DATE, METABOLIX shall
          disclose to TEPHA in writing all METABOLIX-CONTROLLED KNOW-HOW not
          previously disclosed. During the two-year period after the EFFECTIVE
          DATE, each party shall also promptly disclose to the other in writing
          on an ongoing basis all additional KNOW-HOW and IMPROVEMENTS. Subject
          to Article 13 (Confidentiality), METABOLIX grants TEPHA the exclusive
          right and license to use METABOLIX KNOW-HOW and METABOLIX IMPROVEMENTS
          in connection with its license hereunder to the PATENT RIGHTS in the
          FIELD OF USE until termination or expiration of this Agreement;
          provided, however, after expiration of this Agreement, TEPHA shall
          retain a perpetual, royalty-free, non-exclusive license to the
          METABOLIX KNOW-HOW. Subject to Article 13 (Confidentiality) and
          mutually agreed upon royalty and other terms, TEPHA grants METABOLIX
          the exclusive right and license to use TEPHA KNOW-HOW and TEPHA
          IMPROVEMENTS in connection with the PATENT RIGHTS outside the FIELD OF
          USE until the last to expire of any patent rights covering the TEPHA
          IMPROVEMENTS; provided, however, after expiration of this Agreement,
          METABOLIX shall retain a perpetual, royalty-free, non-exclusive
          license to the METABOLIX KNOW-HOW.

     2.5  TEPHA shall have the right to enter into sublicensing agreements for
          the rights, privileges and licenses granted hereunder. Upon any
          termination of this

*    CONFIDENTIAL TREATMENT REQUESTED

                                       6

<Page>

          Agreement, sublicensees' rights shall also terminate, subject to
          Paragraph 14.6 hereof.

     2.6  TEPHA agrees to incorporate terms and conditions substantively similar
          to Articles 1, 2, 5, 7.1, 8, 9, 10, 11, 12, 13, 14.5, 14.6, and 16 of
          this Agreement into its sublicense agreements, that are sufficient to
          enable TEPHA to comply with this Agreement.

     2.7  TEPHA agrees to forward to METABOLIX a copy of any and all sublicense
          agreements promptly upon execution by the parties.

     2.8  TEPHA shall not receive from sublicensees anything of value in lieu of
          cash payments in consideration for any sublicense under this
          Agreement, without the express prior written permission of METABOLIX.

     2.9  Nothing in this Agreement shall be construed to confer any rights upon
          TEPHA by implication, estoppel or otherwise as to any technology or
          patent rights of METABOLIX, MIT or any other entity other than the
          PATENT RIGHTS, regardless of whether such patent rights shall be
          dominant or subordinate to any PATENT RIGHTS.

3.   DUE DILIGENCE

     3.1. TEPHA shall use diligent efforts to bring one or more LICENSED
          PRODUCTS or LICENSED PROCESSES to market through a thorough, vigorous
          and diligent program for exploitation of the PATENT RIGHTS and shall
          continue active, diligent development and marketing efforts for one or
          more LICENSED PRODUCTS or LICENSED PROCESSES throughout the term of
          this Agreement.

     3.2. In addition:

          3.2.1. TEPHA shall raise in connection with the PATENT RIGHTS and
                 allocated for expenditure for efforts under Paragraphs 3.1 and
                 3.2, a cumulative total of investment capital and/or research
                 and development funds of: * from the Effective Date. Such
                 cumulative investment capital and/or research and development
                 funds shall include funds invested or

*    CONFIDENTIAL TREATMENT REQUESTED

                                       7

<Page>

                 expended by a joint venture in which TEPHA owns at least a
                 thirty-three percent (33%) interest provided that such funds
                 are used substantially for the development and marketing of
                 LICENSED PRODUCTS and LICENSED PROCESSES.

          3.2.2. TEPHA shall use commercially reasonable efforts to promptly and
                 diligently generate data and perform tests and studies
                 sufficient to file, and shall file, an application for approval
                 by the FDA of a first LICENSED PRODUCT *.

          3.2.3. TEPHA shall obtain FDA approval of such first LICENSED PRODUCT
                 *.

          3.2.4. TEPHA shall keep METABOLIX informed of progress in its efforts
                 to develop and commercialize LICENSED PRODUCTS and PROCESSES.
                 METABOLIX shall have the right to contact a representative of
                 TEPHA periodically by telephone to discuss TEPHA's progress
                 with the development of LICENSED PRODUCTS and PROCESSES and
                 sales of such LICENSED PRODUCTS and PROCESSES once launched. In
                 addition, on or before March 1 of each year after the EFFECTIVE
                 DATE until the first commercial sale of a LICENSED PRODUCT,
                 TEPHA shall make a written annual summary report to METABOLIX
                 covering the preceding year ending December 31, regarding the
                 progress toward commercial use of LICENSED PRODUCTS and
                 PROCESSES. All information disclosed by TEPHA to METABOLOX
                 under this provision shall be deemed the Confidential
                 Information (as further discussed in Paragraph 13.1) of TEPHA.

     3.3. TEPHA's failure to perform in accordance with Paragraphs 3.1 and 3.2
          above shall be grounds for METABOLIX to terminate this Agreement
          pursuant to Paragraph 14.3 hereof; provided, however, as to Paragraphs
          3.2.2 and 3.2.3, if during the cure period provided in Paragraph 14.3,
          TEPHA shall demonstrate to the reasonable satisfaction of METABOLIX
          that TEPHA shall have expended good faith and diligent efforts using
          reasonable resources to meet the milestone(s)

*    CONFIDENTIAL TREATMENT REQUESTED

                                       8

<Page>

          and that circumstances beyond TEPHA'S control precluded TEPHA from
          performing in accordance with Paragraph 3.2.2 or 3.2.3, then the time
          for performance of such milestone(s) shall be extended for an
          additional period of six (6) months, or such other period as may be
          mutually agreed.

4.   ROYALTIES

     4.1. For the rights, privileges and license granted hereunder, TEPHA shall
          pay royalties to METABOLIX in the manner hereinafter provided until
          the expiration of the last to expire of the PATENT RIGHTS or until
          this Agreement shall earlier be terminated:

          4.1.1. A License Issue Fee of *, which said License Issue Fee shall be
                 deemed earned and due in three parts: * in investment capital
                 and/or research and development funds in connection with the
                 PATENT RIGHTS; * due upon the raising by TEPHA of *
                 (cumulatively) in investment capital and/or research and
                 development funds in connection with the PATENT RIGHTS; and *
                 due upon the raising by TEPHA of * (cumulatively) in investment
                 capital and/or research and development funds in connection
                 with the PATENT RIGHTS; provided, however, the full amount of
                 the License Issue Fee shall be due on the third anniversary of
                 the Effective Date, whether or not TEPHA shall have raised such
                 investment capital and/or research and development funds.

          4.1.2. Milestone payments as follows: * due on filing for approval of
                 the first LICENSED PRODUCT; and * due on FDA approval of the
                 first LICENSED PRODUCT.

          4.1.3. License Maintenance Fees of * per year payable on January 1,
                 2003 and on each subsequent January 1 during the term of this
                 Agreement; provided, however, License *.

          4.1.4. Running Royalties of * of NET SALES of LICENSED PRODUCTS and
                 LICENSED PROCESSES by TEPHA and its sublicensees .

*    CONFIDENTIAL TREATMENT REQUESTED

                                       9

<Page>

          4.1.5. A * share of gross sublicensing revenue (including sublicense
                 issue fees, milestone payments, license maintenance fees and
                 similar consideration but excluding sublicensing revenue from
                 NET SALES covered in Paragraph 4.1.4 above) received by
                 LICENSEE.

     4.2. All payments due hereunder shall be paid in full, without deduction of
          taxes or other fees which may be imposed by any government, except as
          otherwise provided in Paragraph 1.5.2.

     4.3. No multiple royalties shall be payable because any LICENSED PRODUCT,
          its manufacture, use, lease or sale are or shall be covered by more
          than one PATENT RIGHTS patent application or PATENT RIGHTS patent
          licensed under this Agreement.

     4.4. Royalty payments shall be paid in the United States dollars in
          Cambridge, Massachusetts, or at such other place as METABOLIX may
          reasonably designate consistent with the laws and regulations
          controlling in any foreign country. If any current conversion shall be
          required in connection with the payment of royalties hereunder, such
          conversion shall be made by using the exchange rate prevailing at the
          Chase Manhattan Bank (N.A.) on the last business day of the calendar
          quarterly reporting period to which such royalty payments relate.

     4.5. To the extent that TEPHA shall obtain subsequent to the EFFECTIVE DATE
          licenses to third party patents or other intellectual property that
          are necessary to manufacture or sell LICENSED PRODUCTS or LICENSED
          PROCESSES in the FIELD OF USE, TEPHA may deduct from the Running
          Royalty due to METABOLIX under Paragraph 4.1.4, * of the Running
          Royalties due on such third party patents or intellectual property up
          to an amount equal to * of the Running Royalties due hereunder.

5.   REPORTS AND RECORDS

     5.1. TEPHA shall keep full, true and accurate books of account containing
          all particulars that may be necessary for the purpose of showing the
          amounts payable

*    CONFIDENTIAL TREATMENT REQUESTED

                                       10

<Page>

          to METABOLIX hereunder. Said books of account shall be kept at TEPHA's
          principal place of business or the principal place of business of the
          appropriate division of TEPHA to which this Agreement relates. Said
          books and the supporting data shall be open at all reasonable times
          for three (3) years following the end of the calendar year to which
          they pertain, to the inspection of METABOLIX or its agents for the
          purpose of verifying TEPHA's royalty statement or compliance in other
          respect with this Agreement. Should such inspection lead to the
          discovery of a greater than Ten Percent (10%) discrepancy in reporting
          to METABOLIX' detriment, TEPHA agrees to pay the full cost of such
          inspection.

     5.2. TEPHA shall deliver to METABOLIX true and accurate reports, giving
          such particulars of the business conducted by TEPHA and its
          sublicensees under this Agreement as shall be pertinent to diligence
          under Article 3 and royalty accounting hereunder: before the first
          commercial sale of a LICENSED PRODUCT or LICENSED PROCESS, annually,
          on January 31 of each year; and after the first commercial sale of a
          LICENSED PRODUCT or LICENSED PROCESS, quarterly, within sixty (60)
          days after March 31, June 30, September 30 and December 31, of each
          year. These reports shall include at least the following:

          5.2.1. number and total billings of LICENSED PRODUCTS falling solely
                 within the METABOLIX PATENT RIGHTS manufactured, used or sold
                 by TEPHA and its sublicensees;

          5.2.2. number and total billings for LICENSED PRODUCTS falling solely
                 within the MIT PATENT RIGHTS manufactured, used or sold by
                 TEPHA and its sublicensees;

          5.2.3. number and total billings for LICENSED PRODUCTS falling within
                 both the METABOLIX PATENT RIGHTS and the MIT PATENT RIGHTS
                 manufactured, used or sold by TEPHA and its sublicensees;

          5.2.4. accounting for all LICENSED PROCESSES used or sold by TEPHA and
                 its sublicensees, along with a verification as to each LICENSED

*    CONFIDENTIAL TREATMENT REQUESTED

                                       11

<Page>

                 PROCESS stating whether it shall fall solely within the
                 METABOLIX PATENT RIGHTS, solely within the MIT PATENT RIGHTS or
                 both within the METABOLIX PATENT RIGHTS and the MIT PATENTS
                 RIGHTS.;

          5.2.5. deductions applicable as provided in Paragraph 1.5;

          5.2.6. Running Royalties due under Paragraph 4.1.4.;

          5.2.7. royalties due on payments from sublicensees under paragraph
                 4.1.5.;

          5.2.8. total royalties due; and

          5.2.9. names and addresses of all sublicensees of TEPHA.

          TEPHA shall endeavor to obtain similar information from its
          sublicensees and shall provide such information which is obtained to
          METABOLIX.

     5.3. With each such report submitted, TEPHA shall pay to METABOLIX the
          royalties due and payable under this Agreement. If no royalties shall
          be due, TEPHA shall so report.

     5.4. On or before the ninetieth (90th) day following the close of TEPHA's
          fiscal year, TEPHA shall provide METABOLIX with TEPHA's certified
          financial statements for the preceding fiscal year including, at a
          minimum, a balance sheet and an operating statement.

     5.5. The amounts due under Articles 4 and 6 shall, if overdue, bear
          interest until payment a per annum rate * in effect at the Chase
          Manhattan Bank (N.A.) on the due date. The payment of such interest
          shall not foreclose METABOLIX from exercising any other rights it may
          have as a consequence of the lateness of any payment.

6.   PATENT PROSECUTION

     6.1. Throughout the term of this Agreement, TEPHA, at its own expense,
          shall file, prosecute and maintain those METABOLIX PATENT RIGHTS
          listed on Appendix B in METABOLIX' name; provided, however, METABOLIX
          shall be entitled to review and comment upon in a timely manner all
          actions undertaken in

*    CONFIDENTIAL TREATMENT REQUESTED

                                       12

<Page>

          the prosecution of all patents and applications. TEPHA agrees to seek
          strong, broad claims in the best interest of METABOLIX and shall not
          abandon the subject matter of any substantive claim without the prior
          written permission of METABOLIX, such permission not to be
          unreasonably withheld. If TEPHA shall elect not to file, prosecute, or
          maintain any such METABOLIX PATENT RIGHT, TEPHA shall so notify
          METABOLIX in writing with at least thirty (30) days notice prior to
          any filing, action, payment or the like being due, in which event
          METABOLIX shall have the right to file, prosecute, or maintain such
          METABOLIX PATENT RIGHT, and TEPHA shall have no further license rights
          as to such METABOLIX PATENT RIGHT application or patent under this
          Agreement.

     6.2. Payment of all out-of-pocket fees and costs relating to the filing,
          prosecution, and maintenance of those METABOLIX PATENT RIGHTS listed
          on Appendix B shall be the responsibility of TEPHA, whether such fees
          and costs were incurred before or after the Effective Date of this
          Agreement. Payment for out-of-pocket costs incurred by METABOLIX prior
          to the Effective Date shall be made in three parts:

          6.2.1. Twenty-Five Percent (25%) on or before a date six (6) months
                 from the Effective Date of this Agreement;

          6.2.2. Twenty-Five Percent (25%) on or before a date nine (9) months
                 from the Effective Date of this Agreement;

          6.2.3. The remaining Fifty Percent (50%) on or before a date fifteen
                 (15) months from the Effective Date of this Agreement.

7.   INFRINGEMENT

     7.1. Each party shall inform the other promptly in writing of any alleged
          infringement of the PATENT RIGHTS by a third party and of any
          available evidence thereof.

     7.2. During the term of this Agreement, TEPHA shall have the right, but
          shall not be obligated, to prosecute at its own expense all
          infringements of the PATENT

*    CONFIDENTIAL TREATMENT REQUESTED

                                       13

<Page>

          RIGHTS in the FIELD OF USE and, in furtherance of such right,
          METABOLIX hereby agrees that TEPHA may join METABOLIX as a party
          plaintiff in any such suit, without expense to METABOLIX. The total
          cost of any such infringement action commenced solely by TEPHA shall
          be borne by TEPHA. In the event that TEPHA shall have exercised its
          right to bring an action, TEPHA shall be responsible for defending
          against any counterclaims alleging invalidity or unenforceability of a
          PATENT RIGHT and for prosecuting the action through to settlement or
          other final disposition. In the event that TEPHA shall undertake the
          enforcement of the PATENT RIGHTS in the FIELD OF USE by litigation,
          TEPHA may withhold up to * of the Running Royalties otherwise
          thereafter due to METABOLIX under Section 4.1.4 and apply the same
          toward reimbursement of up to * of TEPHA'S expenses, including
          reasonable attorneys' fees, in connection therewith.

     7.3. If within six (6) months after having been notified of any alleged
          infringement, TEPHA shall have been unsuccessful in persuading the
          alleged infringer to desist and shall not have brought and shall not
          be diligently prosecuting an infringement action, or if TEPHA shall
          notify METABOLIX at any time prior thereto of its intention not to
          bring suit against any alleged infringer, then, and in those events,
          only, METABOLIX shall have the right, but shall not be obligated, to
          prosecute at its own expense any infringement of the PATENTS RIGHTS in
          the FIELD of USE. In furtherance of such right, TEPHA hereby agrees
          that METABOLIX may include TEPHA as a party plaintiff in any such
          suit, without expense to TEPHA. The total cost of any such
          infringement action commenced or defended solely by METABOLIX shall be
          borne by METABOLIX, and METABOLIX shall be responsible for defending
          against any counterclaims alleging invalidity or unenforceability of a
          PATENT RIGHT.

     7.4. Any recovery of damages by the prosecuting party for any such suit
          shall be applied first in satisfaction of any unreimbursed expenses
          and legal fees of such party relating to the suit, and next toward
          reimbursement of METABOLIX for any royalties past due or withheld and
          applied pursuant to Paragraph 7.2, if applicable.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       14

<Page>

          The balance remaining from any such recovery shall be divided with *
          to the non-prosecuting party and any remaining balance to the
          prosecuting party.

     7.5. In the event of the institution of any suit by a third party against
          METABOLIX, TEPHA or its sublicensees for patent infringment involving
          the PATENT RIGHTS in the FIELD OF USE, the party sued shall promptly
          notify the other party in writing. TEPHA shall have the right, but not
          the obligation, to defend such suit at its own expense. If TEPHA shall
          elect not to defend, TEPHA shall promptly notify METABOLIX. METABOLIX
          shall have the right, but not the obligation, to defend such suit at
          its expense.

     7.6. If TEPHA shall exercise its rights pursuant to Section 7.5 to defend
          the PATENT RIGHTS, then * of TEPHA'S Running Royalty obligation in
          Section 4.1.4 during the pendency of defense in the proceeding shall
          be held in an interest-bearing escrow account by TEPHA until a final
          decision shall be rendered by a court or administrative tribunal of
          competent jurisdiction from which no appeal can be or is taken
          provided that:

          7.6.1. If the enforceability of all material claims in such PATENT
                 RIGHT claiming the LICENSED PRODUCT or PROCESS is upheld by a
                 court or other legal or administrative tribunal from which no
                 appeal is or can be taken, then the amount of Running Royalties
                 withheld during the period of escrow, plus all accrued
                 interest, shall be promptly paid to METABOLIX; or

          7.6.2. If one or more claims in such PATENT RIGHT covering the
                 LICENSED PRODUCT or PROCESS shall be held to be invalid or
                 otherwise unenforceable by a court or other legal or
                 administrative tribunal in any country from which no appeal is
                 or can be taken or the scope thereof is modified and, as a
                 result such PATENT RIGHT no longer offers substantial
                 protection to a LICENSED PRODUCT or PROCESS in such country,
                 then the amount of Running Royalties withheld during the period
                 of escrow shall not be owed to METABOLIX; TEPHA shall be
                 entitled to all payments and accrued interest in the escrow
                 account; and the Running

*    CONFIDENTIAL TREATMENT REQUESTED

                                       15

<Page>

                 Royalties otherwise payable shall be abated in their entirety
                 with respect to NET SALES of LICENSED PRODUCTS covered only by
                 such PATENT RIGHT in the country in which such claims were so
                 held invalid or unenforceable or so modified.

     7.7. In any suit as either party may institute to enforce or defend the
          PATENT RIGHTS pursuant to this Agreement, the other party hereto
          shall, at the request and expense of the party initiating such suit,
          cooperate in all respects and, to the extent possible, have its
          employees testify when requested and make available relevant records,
          papers, information, samples, specimens and the like. The parties
          shall keep one another informed of the status of and of their
          respective activities regarding any litigation or settlement thereof
          concerning the PATENT RIGHTS in the FIELD of USE or LICENSED PRODUCTS
          or PROCESSES ; provided, however, that no settlement or consent
          judgement or other voluntary final disposition of any suit defended or
          action brought by a party pursuant to this Article 7 may be entered
          into without the consent of the other party, such consent not to be
          unreasonably withheld or delayed. As to the MIT PATENT RIGHTS, no
          settlement, consent judgement or other voluntary final disposition of
          the suit may be entered into without the consent of MIT which consent
          shall not unreasonably be withheld. TEPHA shall indemnify MIT against
          any order for costs that may be made against MIT in proceedings
          commenced and defended solely by TEPHA.

     7.8. TEPHA, during the period of this Agreement, shall have the sole right
          in accordance with the terms and conditions herein to sublicense any
          alleged infringer for future use of the PATENT RIGHTS in the FIELD OF
          USE.

8.   PRODUCT LIABILITY

     8.1. TEPHA shall at all times during the term of this Agreement and
          thereafter, indemnify, defend and hold METABOLIX and MIT, their
          directors, trustees, officers, employees and affiliates, harmless
          against all claims and expenses,

*    CONFIDENTIAL TREATMENT REQUESTED

                                       16

<Page>

          arising out of the death of or injury to any person or persons or out
          of any damage to property and against any other claim, proceeding,
          demand, expense and liability of any kind whatsoever resulting from or
          relating to the production, manufacture, sale, use, lease, consumption
          or advertisement of the LICENSED PRODUCTS and/or LICENSED PROCESS(es)
          *.

     8.2. Prior to the first use of a LICENSED PRODUCT for humans, TEPHA shall
          obtain and carry in full force and effect commercial, general
          liability insurance, including product liability insurance, which
          shall protect TEPHA, METABOLIX, and MIT with respect to events covered
          by Paragraph 8.1 above. Such insurance shall be written by a reputable
          insurance company authorized to do business in the Commonwealth of
          Massachusetts, shall list METABOLIX and MIT as additional named
          insureds thereunder, shall be endorsed to include product liability
          coverage and shall require thirty (30) days written notice to be given
          to METABOLIX and MIT prior to any cancellation or material change
          thereof. The limits of such insurance shall not be less than * per
          occurrence with an aggregate of * for personal injury including death;
          and * per occurrence with an aggregate of * for property damage. TEPHA
          shall provide METABOLIX with Certificates of Insurance evidencing the
          same.

     8.3. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER
          PARTY, NOR MIT, NOR THEIR RESPECTIVE DIRECTORS, TRUSTEES, OFFICERS,
          EMPLOYEES, AND AFFILIATES MAKE ANY REPRESENTATIONS OR EXTEND ANY
          WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT
          LIMITED TO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR
          PURPOSE, VALIDITY OF PATENT RIGHTS CLAIMS, ISSUED OR PENDING, AND THE
          ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE.
          NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION MADE
          OR WARRANTY GIVEN BY EITHER PARTY OR BY MIT THAT THE PRACTICE OF THE
          LICENSES GRANTED HEREUNDER SHALL NOT

*    CONFIDENTIAL TREATMENT REQUESTED

                                       17

<Page>

          INFRINGE THE PATENT RIGHTS OR OTHER INTELLECTUAL OR PROPRIETARY RIGHTS
          OF ANY THIRD PARTY. * TEPHA, MIT OR THEIR RESPECTIVE DIRECTORS,
          TRUSTEES, OFFICERS, EMPLOYEES AND AFFILIATES BE LIABLE FOR INCIDENTAL
          OR CONSEQUENTIAL DAMAGES OF ANY KIND, INCLUDING ECONOMIC DAMAGE OR
          INJURY TO PROPERTY AND LOST PROFITS, REGARDLESS OF WHETHER SUCH PARTY
          SHALL OR M.I.T. BE ADVISED, SHALL HAVE OTHER REASON TO KNOW, OR IN
          FACT SHALL KNOW OF THE POSSIBILITY OF THE FOREGOING.

9.   EXPORT CONTROLS

     9.1. TEPHA acknowledges that it is subject to United States laws and
          regulations controlling the export of technical data, computer
          software, laboratory prototypes and other commodities (including the
          Arms Export Control Act, as amended and the United States Department
          of Commerce Export Administration Regulations). The transfer of such
          items may require a license from the cognizant agency of the United
          States Government and/or written assurances by TEPHA that TEPHA shall
          not export data or commodities to certain foreign countries without
          prior approval of such agency. METABOLIX neither represents that a
          license shall not be required nor that, if required, it shall be
          issued.

10.  NON-USE OF NAMES

     10.1. Except as required by law or in raising funding, neither party shall
           use the names or trademarks of the other, nor of MIT, nor any
           adaptation thereof, nor the names of any of the other party's or
           MIT's employees, in any advertising, promotional or sales literature
           without prior written consent obtained from such party, or MIT, or
           said employee, in each case, such consent not to be unreasonably
           withheld, except that TEPHA may state that it is licensed by
           METABOLIX, or MIT, as

*    CONFIDENTIAL TREATMENT REQUESTED

                                       18

<Page>

          applicable, under one or more of the patents and/or applications
          comprising the METABOLIX PATENT RIGHTS, or the MIT PATENT RIGHTS,
          respectively. TEPHA may, however, use the name of any employee of
          METABOLIX who is a consultant or member of an advisory board of TEPHA,
          with their permission, and provided, also, that their affiliation with
          METABOLIX is identified.

11.  ASSIGNMENT

     11.1. Except as expressly provided in Article 2, neither party shall
           directly or indirectly sell, transfer, assign, or delegate in whole
           or in part this Agreement, or any rights, duties, obligations or
           liabilities under this Agreement (collectively "assign"), by
           operation of law or otherwise without the prior written consent of
           the other party, such consent not to be unreasonably withheld or
           delayed; provided, however, so long as the assignee shall not be a
           competitor of the other party, either party shall have the right to
           assign all of its rights, duties, obligations and liabilities under
           this Agreement to any AFFILIATE or in connection with any sale,
           merger, consolidation, recapitalization or reorganization involving
           in each case the sale of all or substantially all of the capital
           stock of the party or the assets of such party to which this
           Agreement relates. This Agreement shall inure to the benefit of and
           be binding upon the permitted successors and assigns of METABOLIX and
           TEPHA.

12.  DISPUTE RESOLUTION

     12.1. Except for the right of either party to apply to a court of competent
           jurisdiction for a temporary restraining order, a preliminary
           injunction or other equitable relief to preserve the status quo or to
           prevent irreparable harm, and except for any dispute relating to
           patent validity or infringement, any and all claims, disputes or
           controversies arising under, out of or in connection with the
           Agreement, shall be mediated in good faith. The party raising such
           dispute shall promptly advise the other party of such claim, dispute
           or controversy in a writing which describes in

*    CONFIDENTIAL TREATMENT REQUESTED

                                       19

<Page>

           reasonable detail the nature of such dispute. If the parties by their
           senior management representatives shall be unable to resolve the
           dispute within thirty (30) days, then by no later than forty (40)
           business days after the recipient has received such notice of
           dispute, each party shall have selected for itself a representative
           who shall have the authority to bind such party, and shall
           additionally have advised the other party in writing of the name and
           title of such representative. By no later than sixty (60) business
           days after the date of such notice of dispute, such representatives
           shall schedule a date for a mediation hearing with the Cambridge
           Dispute Settlement Center or Endispute Inc. in Cambridge,
           Massachusetts. The parties shall enter into good faith mediation and
           shall share the costs equally. If the representatives of the parties
           have not been able to resolve the dispute within thirty (30) business
           days after such mediation hearing, the parties shall have the right
           to pursue any other remedies legally available to resolve such
           dispute in either the Courts of the Commonwealth of Massachusetts, or
           in the United States District Court for the District of
           Massachusetts, to whose jurisdiction for such purposes METABOLIX and
           TEPHA each hereby irrevocably consents and submits.

     12.2. Notwithstanding the foregoing, nothing in this Article shall be
           construed to waive any rights or timely performance of any oblations
           under this Agreement.

13.  CONFIDENTIALTIY

     13.1. Both METABOLIX and TEPHA agree that all information disclosed to the
           other party shall be deemed "Confidential Information" of the
           disclosing party. In particular, "Confidential Information" shall be
           deemed to include, but not be limited to, KNOW-HOW, trade secrets,
           information, ideas, inventions, materials, samples, processes,
           procedures, methods, formulations, protocols, packaging designs and
           materials, test data, future development plans, "Product" launch
           date, technological know-how and engineering, manufacturing,
           regulatory, marketing,

*    CONFIDENTIAL TREATMENT REQUESTED

                                       20

<Page>

           servicing, sales, or financial matters relating to the disclosing
           party and its business.

     13.2. During the term of this Agreement and thereafter each party shall
           maintain all Confidential Information in confidence and shall not
           disclose any Confidential Information to any third party or use any
           such information for any unauthorized purpose. Each party may use
           such Confidential Information only to the extent required to
           accomplish the purposes of this Agreement. Both parties shall take
           precautions as each normally takes with its own confidential and
           proprietary information to prevent disclosure to third parties, but
           no less than reasonable precautions.

     13.3. Both parties agree that, notwithstanding the above, the obligations
           of confidentiality and nonuse shall not apply to:

          13.3.1. Information that at the time of disclosure is, or thereafter
                  becomes, generally known or available to the public, through
                  no wrongful act or failure to act on the part of the receiving
                  party;

          13.3.2. Information that was known by or in the possession of the
                  receiving party at the time of receiving such information from
                  the disclosing party, as evidenced by written records;

          13.3.3. Information obtained by the receiving party from a third-party
                  source who is not breaching a commitment of confidentiality to
                  the disclosing party by revealing such information to the
                  receiving party;

          13.3.4. Information that is developed independently by the receiving
                  party without use of confidential information of the other
                  party, as evidenced by written records;

          13.3.5. Information that is the subject of a granted written
                  permission to disclose that is issued by the disclosing party
                  to the other party;

          13.3.6. Information that is required to be disclosed pursuant to the
                  law, by request of the FDA or other government authority or
                  for medical or safety reasons, but only to the extent required
                  to be disclosed by the FDA or other government authority; or

*    CONFIDENTIAL TREATMENT REQUESTED

                                       21

<Page>

          13.3.7. Information provided to consultants, subcontractors or agents
                  for purposes consistent with this Agreement pursuant to a
                  non-disclosure agreement with said parties.

     13.4. Both Parties shall make diligent efforts to ensure that all
           employees, consultants, agents and subcontractors who may have access
           to Confidential Information of the other party, and any other third
           parties who might have access to Confidential Information, shall sign
           nondisclosure agreements consistent with the terms set forth in this
           Section. No Confidential Information shall be disclosed to any
           employees, subcontractors, agents, consultants or third parties who
           do not have a need to receive such information for the purposes of
           this Agreement.

14.  TERMINATION

     14.1. If TEPHA shall cease to carry on its business, this Agreement shall
           terminate upon notice by METABOLIX, except as provided in Article 11
           (Assignment).

     14.2. Should TEPHA fail to make any payment whatsoever due and payable to
           METABOLIX hereunder, METABOLIX shall have the right to terminate this
           Agreement effective on sixty (60) days' notice, unless TEPHA shall
           make all such payments to METABOLIX, within said sixty (60) day
           period. Upon the expiration of the sixty (60) day period, if TEPHA
           shall not have made all such payments to METABOLIX, the rights,
           privileges and license granted hereunder shall automatically
           terminate.

     14.3. Upon any material breach or default of this Agreement by TEPHA, other
           than those occurrences set out in Paragraphs 14.1 and 14.2
           hereinabove, which shall always take precedence in that order over
           any material breach or default referred to in this Paragraph 14.3,
           METABOLIX shall have the right to terminate this Agreement and the
           rights, privileges and license granted hereunder effective on one
           hundred and twenty (120) days' notice to TEPHA. Such termination
           shall become automatically effective unless TEPHA shall have cured
           any such material breach or default prior to the expiration of the
           one hundred and twenty (120) day

*    CONFIDENTIAL TREATMENT REQUESTED

                                       22

<Page>

           period. Upon any material breach or default of this Agreement by
           METABOLIX, TEPHA shall have the right to terminate this Agreement and
           the rights, privileges and license granted hereunder effective on one
           hundred and twenty (120) days' notice to METABOLIX. Such termination
           shall become automatically effective unless METABOLIX shall have
           cured any such material breach or default prior to the expiration of
           the one hundred and twenty (120) day period.

     14.4. TEPHA shall have the right to terminate this Agreement at any time on
           six (6) months' notice to METABOLIX, and upon payment of all amounts
           due METABOLIX through the effective date of the termination.

     14.5. Upon termination of this Agreement for any reason, nothing herein
           shall be construed to release either party from any obligation that
           matured prior to the effective date of such termination; and Articles
           1, 8, 9, 10, 12, 13, 14.5, 14.6, and 16 shall survive any such
           termination. TEPHA and any sublicensee thereof may, however, after
           the effective date of such termination, sell all LICENSED PRODUCTS in
           inventory, and complete LICENSED PRODUCTS in the process of
           manufacture at the time of such termination and sell the same,
           provided that TEPHA shall pay to METABOLIX the Running Royalties
           thereon as required by Article 4 of this Agreement and shall submit
           the reports required by Article 5 hereof on the sales of LICENSED
           PRODUCTS.

     14.6. Upon termination of this Agreement for any reason, any sublicense not
           then in default shall continue in full force and effect except that
           METABOLIX shall be substituted in place of the TEPHA, and METABOLIX
           shall have no obligations under such sublicense beyond their
           obligations herein.

     14.7. Upon termination of this AGREEMENT for any reason (except expiration
           or termination by TEPHA for breach by METABOLIX under Paragraph
           14.3), TEPHA shall, grant and hereby grants METABOLIX a nonexclusive
           license, with the right to sublicense, to all information then in
           TEPHA's possession relevant to the commercialization of LICENSED
           PRODUCTS and/or LICENSED PROCESSES, including, but not limited to,
           KNOW-HOW and

*    CONFIDENTIAL TREATMENT REQUESTED

                                       23

<Page>

           IMPROVEMENTS owned or controlled by TEPHA as of the effective date of
           termination (whether such know-how and improvements shall be owned or
           CONTROLLED by TEPHA during the two-year period after the EFFECTIVE
           DATE or at any time during the term of this Agreement), research
           results, toxicology data, assays, preclinical data, prototypes,
           manufacturing processes including cell lines and unused, unexpired
           amounts of LICENSED PRODUCTS, clinical results, regulatory
           submissions, suppliers and customer lists. In such event TEPHA shall
           receive a royalty equal to * of the gross amount of consideration, if
           any, subsequently received by METABOLIX with respect to the LICENSED
           PRODUCTS and LICENSED PROCESSES].

15.  PAYMENTS, NOTICES AND OTHER COMMUNICATIONS

     15.1. Any payment, notice or other communication pursuant to this Agreement
           shall be sufficiently made or given on the date of mailing if sent to
           such party by certified first class mail, postage prepaid, return
           receipt requested addressed to it at its address below or as it shall
           designate by written notice given to the other party:

     In the case of METABOLIX:
     President
     METABOLIX, Inc.
     303 Third Street
     Cambridge, Massachusetts 02142

     In the case of TEPHA:
     President
     TEPHA, Inc.
     303 Third Street
     Cambridge, Massachusetts 02142

16.  MISCELLANEOUS PROVISIONS

     16.1. This Agreement shall be construed, governed, interpreted and applied
           in accordance with the laws of the Commonwealth of Massachusetts,
           U.S.A., except

*    CONFIDENTIAL TREATMENT REQUESTED

                                       24

<Page>

           that questions affecting the construction and effect of any patent
           shall be determined by the law of the country in which the patent was
           granted.

     16.2. The parties hereto acknowledge that this Agreement sets forth the
           entire Agreement and understanding of the parties hereto as to the
           subject matter hereof, and shall not be subject to any change or
           modification except by the execution of a written instrument
           subscribed to by the parties hereto.

     16.3. The provisions of this Agreement are severable, and in the event that
           any provisions of this Agreement shall be determined to be invalid or
           unenforceable under any controlling body of the law, such invalidity
           or unenforceability shall not in any way affect the validity or
           enforceability of the remaining provisions hereof.

     16.4. The failure of either party to assert a right hereunder or to insist
           upon compliance with any term or condition of this Agreement shall
           not constitute a waiver of that right or excuse a similar subsequent
           failure to perform any such term or condition by the other party.

     16.5. TEPHA agrees to mark the LICENSED PRODUCTS sold in the United States
           with all applicable United States patent numbers. All LICENSED
           PRODUCTS shipped to or sold in other countries shall be marked in
           such a manner as to conform with the patent laws and practice of the
           country of manufacture or sale.

     IN WITNESS WHEREOF, the parties have duly executed this Agreement the day
and year set forth below.

METABOLIX, INC.

By:    /s/ Edward M. Muller
       ------------------------------
Name:  Edward M. Muller
Title: President
Date:  10/1/99

*    CONFIDENTIAL TREATMENT REQUESTED

                                       25

<Page>

TEPHA, INC.

By:    /s/ Simon F. Williams
       ------------------------------
Name:  Simon F. Williams
Title: President
Date:  October 1, 1999

*    CONFIDENTIAL TREATMENT REQUESTED

                                       26

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00111-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00111-of-00352.parquet"}]]